Injectable amphotericin B: mix-ups between lipid and non-lipid formulations.
(1) Amphotericin B is a standard antifungal drug with a narrow therapeutic margin. It has potentially severe adverse effects, especially renal and cardiac toxicity; (2) Three injectable forms of amphotericin B are currently available in France and elsewhere. They mainly differ in their dose regimens; (3) Cases of fatal overdose have occurred following confusion between the various injectable formulations; (4) Measures intended to prevent such errors include: specific training of healthcare staff; informing users that the different injectable forms of amphotericin B are not interchangeable; simultaneously mentioning the excipient and the international nonproprietary name (INN) and the brand name; remembering the maximum dose of the conventional formulation; noting the dose per kilogram per day, as well as the total daily dose; and if possible, involving the patient.